No matching results for ''
Tip: Try a valid symbol or a specific company name for relevant results
Work & Management
UK Markets closed
What the budget means for your taxes, housing, pensions and more
How announcements made by chancellor Rishi Sunak will impact your income and finances
Adverum Biotechnologies, Inc. (0HA3.L)
LSE - LSE Delayed price. Currency in USD
Add to watchlist
At close: 2:30PM GMT
471 reactions on $0HA3.L conversation
Sign in to post a message.
Does anyone ever have a company that you're really bullish on for absolutely no reason? For me Adverum is that, maybe it's because their products would have benefited now deceased family, but who knows. Hope you're all doing well!
On a CE zoom meeting tonight with a local Retinal group, discussing AMD etc.
Will ask about ADVM/outlook ......and competitors like Port delivery systems from NVS & Roche.
Port tech seems moot if gene therapy works.
Will report back & probably buy more if get good feedback from those MDs in the trenches.
something is up premarket . looks like open will be up 6% or so.
Hang on this stock is going to run up as soon as the retail guys see it is a gene therapy that has a product
with potential for several billion in sales annually . I can not be the only one who can see the value of this company.
I too owned Edit for a few years from the 20 s until just a week ago. Beam from low 20 s
Saw you EDIT for a few years your words pretty much hit the nail on head.
I am out of EDIT as of a couple weeks ago got in a few years ago so it ended well.
ADVM has product that should be available in a couple few years. I watched this at $ 4 and $ 7 and missed my chance for easy money .But I think if they have 85% long term therapy success with either shot on goal it will be a multi billion annual sales. I think I am still in early enough to reap huge rewards.
Would like to see more chatter on board to know it is being followed.
My yahoo shows after hours up 12 % at 7 :01 PM Thursday .
What the heck hope it opens at that or above .
Maybe the reddit traders saw that these guys have a way to hold back blindness
AGTC to Present at the 4th Annual Gene Therapy for Rare Disorders Digital Event, February 22-25, 2021
Paul did the local Retinal group give any indications or response as to the one and done therapy ADVM offers?
Macular Degeneration is the holy grail of ocular gene editing.
My eye doctor salivates over wet and dry AMD possibilities
read Saturday company news release 6 for 6 at average 82 weeks . No injections . This is a group that had many dozens a year and now none at 82 weeks that is showing durability .
If this is a cure for millions and they can price in correctly so medicare/medicaid and insurance will pay this is a multi billion dollar therapy. Do not want to hype but really the media should be looking at this . It is gonna be great if they repeat in a pivotal large study .
100 million public offering at how much a share I see this go both ways opion is it a good or bad thing.
very interested in todays ceo keynote in Boston, should be a great week for advm investors.
like getting 1/6 of entire company through a pinhole to cover shorts. regeneron has increased partnership with 7 new partnered programs with ADVERUM. Updated on website
What a manipulation. Read the news:
One of the most extreme valuations belongs to Adverum Biotechnologies Inc. (NASDAQ:ADVM) of Redwood City, California, which is working on several forms of gene therapy for ocular and rare diseases. It sells for more than 3,000 times revenue.
According to its website, Adverum has one drug in Phase 1 clinical trials and two drugs in preclinical trials (animal testing).
For the moment, annual revenue is about $320,000 while the stock's market value is about $1 billion.
Adverum Biotechnologies Announces Completion of Dosing of First Cohort of Patients in the ADVANCE Phase 1/2 Clinical Trial of ADVM-043 Gene Therapy for A1AT Deficiencyhttps://finance.yahoo.com/news/adverum-biotechnologies-announces-completion-dosing-140000701.html
Surpasses Wall Street expectation by .02 cents , that’s good news... now let’s roll !!
Company has no sales channel, operates under NOL every year, can only raise capital by diluting shares/raising debt, has 3 years of cash left with no product, and is about to dilute its shareholders by over $6/share and people are buying it? So bizarre.
Editas (EDIT) is using Adverums AAV's in their own CRISPR ocular trials with a 3 month readout coming soon. I own both.
reasonable price: about $9
Tomorrow is going to be a great day 👍
Marks & Spencer bank to close current accounts and 29 branches
Yahoo Finance UK
SpaceX Starship SN10 finally lands safely before huge explosion minutes later
Women who were ‘short-changed’ on state pension to receive payments
PA Media: Money
© 2021 Verizon Media. All rights reserved.
About our ads